摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N4-(5-chloro-benzo[1,3]dioxol-4-yl)-7-(2-methoxyethoxy)quinazoline-4,6-diamine | 1155336-41-6

中文名称
——
中文别名
——
英文名称
N4-(5-chloro-benzo[1,3]dioxol-4-yl)-7-(2-methoxyethoxy)quinazoline-4,6-diamine
英文别名
——
N4-(5-chloro-benzo[1,3]dioxol-4-yl)-7-(2-methoxyethoxy)quinazoline-4,6-diamine化学式
CAS
1155336-41-6
化学式
C18H17ClN4O4
mdl
——
分子量
388.81
InChiKey
GHASQCOFDPYUHG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.36
  • 重原子数:
    27.0
  • 可旋转键数:
    6.0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    100.75
  • 氢给体数:
    2.0
  • 氢受体数:
    8.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    BOC-L-脯氨酸N4-(5-chloro-benzo[1,3]dioxol-4-yl)-7-(2-methoxyethoxy)quinazoline-4,6-diamine吡啶盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下, 反应 2.0h, 以75%的产率得到(S)-2-[4-(5-chloro-benzo[1,3]dioxol-4-ylamino)-7-(2-methoxyethoxy)quinazolin-6-ylcarbamoyl]pyrrolidine-2-carboxylic acid tert-butyl ester
    参考文献:
    名称:
    Structure-based virtual screening of Src kinase inhibitors
    摘要:
    Src is an important target in multiple processes associated with tumor growth and development, including proliferation, neovascularization, and metastasis. In this study, hit identification was performed by virtual screening of commercial and in-house compound libraries. Docking studies for the hits were performed, and scoring functions were used to evaluate the docking results and to rank ligand-binding affinities. Subsequently, hit optimization for potent and selective candidate Src inhibitors was performed through focused library design and docking analyses. Consequently, we report that a novel compound '43' with an IC50 value of 89 nM, representing (S)-N-(4-(5-chlorobenzo[d][1,3]dioxol-4-ylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)pyrrolidine-2-carboxamide, is highly selective for Src in comparison to EGFR (IC50 ratio > 80-fold) and VEGFR-2 (IC50 ratio > 110-fold). Compound 43 exerted anti-proliferative effects on Src-expressing PC3 human prostate cancer and A431 human epidermoid carcinoma cells, with calculated IC50 values of 1.52 and 0.78 mu M, respectively. Moreover, compound 43 (0.1 mu M) suppressed the phosphorylation of extracellular signal-regulated kinases and p90 ribosomal S6 kinase, downstream molecules of Src, in a time-dependent manner, in both PC3 and A431 cell lines. The docking structure of compound 43 with Src disclosed that the chlorobenzodioxole moiety and pyrrolidine ring of C-6 quinazoline appeared to fit tightly into the hydrophobic pocket of Src. Additionally, the pyrrolidine NH forms a hydrogen bond with the carboxyl group of Asp348. These results confirm the successful application of virtual screening studies in the lead discovery process, and suggest that our novel compound 43 can be an effective Src inhibitor candidate for further lead optimization. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2009.02.054
  • 作为产物:
    描述:
    (5-chloro-benzo[1,3]dioxol-4-yl)[7-(2-methoxyethoxy)-6-nitro-quinazolin-4-yl]amine盐酸铁粉 作用下, 以 乙醇 为溶剂, 反应 1.0h, 以95%的产率得到N4-(5-chloro-benzo[1,3]dioxol-4-yl)-7-(2-methoxyethoxy)quinazoline-4,6-diamine
    参考文献:
    名称:
    Structure-based virtual screening of Src kinase inhibitors
    摘要:
    Src is an important target in multiple processes associated with tumor growth and development, including proliferation, neovascularization, and metastasis. In this study, hit identification was performed by virtual screening of commercial and in-house compound libraries. Docking studies for the hits were performed, and scoring functions were used to evaluate the docking results and to rank ligand-binding affinities. Subsequently, hit optimization for potent and selective candidate Src inhibitors was performed through focused library design and docking analyses. Consequently, we report that a novel compound '43' with an IC50 value of 89 nM, representing (S)-N-(4-(5-chlorobenzo[d][1,3]dioxol-4-ylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)pyrrolidine-2-carboxamide, is highly selective for Src in comparison to EGFR (IC50 ratio > 80-fold) and VEGFR-2 (IC50 ratio > 110-fold). Compound 43 exerted anti-proliferative effects on Src-expressing PC3 human prostate cancer and A431 human epidermoid carcinoma cells, with calculated IC50 values of 1.52 and 0.78 mu M, respectively. Moreover, compound 43 (0.1 mu M) suppressed the phosphorylation of extracellular signal-regulated kinases and p90 ribosomal S6 kinase, downstream molecules of Src, in a time-dependent manner, in both PC3 and A431 cell lines. The docking structure of compound 43 with Src disclosed that the chlorobenzodioxole moiety and pyrrolidine ring of C-6 quinazoline appeared to fit tightly into the hydrophobic pocket of Src. Additionally, the pyrrolidine NH forms a hydrogen bond with the carboxyl group of Asp348. These results confirm the successful application of virtual screening studies in the lead discovery process, and suggest that our novel compound 43 can be an effective Src inhibitor candidate for further lead optimization. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2009.02.054
点击查看最新优质反应信息